VIAGRA 50 MG
SILDENAFIL (SILDENAFIL CITRATE) : 50 MG · DIN 02239767 · BGP PHARMA ULC
Health Canada status: MARKETED
What is VIAGRA?
VIAGRA 50 MG contains SILDENAFIL (SILDENAFIL CITRATE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02239767, held by BGP PHARMA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VIAGRA used for?
Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02239767 |
|---|---|
| Brand name | VIAGRA |
| Generic / active ingredient | SILDENAFIL (SILDENAFIL CITRATE) : 50 MG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BE03 SILDENAFIL |
| AHFS class | 24:12.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Jul-2023 |
| Original market date | 1999-03-09 00:00:00 |
How is it administered?
Recommended 50 mg as needed, 30-60 min before sexual activity (range 0.5-4 hours). Max once daily. Starting dose of 25 mg for elderly, hepatic/renal impairment, or certain drug interactions.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refer to full monograph for specific temperature ranges).
How is it supplied?
Tablets: Blister packs of 4 or 8. Orodispersible films: Cartons of 2 or 4 individually wrapped films.
Contraindications
Nitrate therapy (regular/intermittent); guanylate cyclase stimulators (e.g. riociguat); hypersensitivity to components; men for whom sexual activity is inadvisable; previous episode of NAION.
Warnings and precautions
Potential cardiac risk of sexual activity; symptomatic hypotension with alpha-blockers; sudden hearing loss; sudden loss of vision (NAION); priapism (erections >4 hours); SJS/TEN.
What can be used instead?
Other Canadian products sharing ATC code G04BE03 SILDENAFIL. 42 of 127 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-SILDENAFIL | 100 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02479826 |
| ACCEL-SILDENAFIL | 25 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02479796 |
| ACCEL-SILDENAFIL | 50 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02479818 |
| AG-SILDENAFIL TABLETS | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02503344 |
| APO-SILDENAFIL | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02248203 |
| APO-SILDENAFIL | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02248201 |
| APO-SILDENAFIL | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02248202 |
| AURO-SILDENAFIL | 100 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414384 |
| AURO-SILDENAFIL | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414368 |
| AURO-SILDENAFIL | 50 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414376 |
Who else supplies SILDENAFIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SILDENAFIL appears in 3124 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.